Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
Company Overview
December 2017
NASDAQ: MDGL
1
2
Any statements, other than statements of historical facts, made in this presentation regarding our future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters; our ability to obtain additional financing; the estimated size of the market for our product candidates, the timing and success of our development and commercialization of our anticipated product candidates; and the availability of alternative therapies for our target market, are, or may be deemed, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “could,” “should,” “would,” “anticipate,” “believe,” “estimate,” “continue,” “design,” “expect,” “intend,” “plan,” “potential,” “predict,” “seek” or the negative of these words and similar expressions and their variants may identify forward-looking statements.
These forward-looking statements reflect management’s current expectations, are based on certain assumptions and involve certain risks and uncertainties, which change over time. Our actual results may differ materially from the results discussed in these forward-looking statements due to various factors. Important factors that may cause actual results to differ materially from the results discussed in these forward-looking statements include, but are not limited to, risks related to securing and maintaining relationships with collaborators; risks relating to our clinical trials; risks relating to the commercialization, if any, of our proposed product candidates (such as marketing, regulatory, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property; and risks related to our cash resources and ability to obtain working capital to fund our proposed operations. Further information regarding on the factors that could affect our business, financial conditions and results of operations are contained our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These forward-looking statements represent management’s expectations as of the date hereof only, and we specifically disclaim any duty or obligation to update forward-looking statements as a result of subsequent events or developments, except as required by law.
Forward Looking Statements
3
Madrigal Investment Highlights
Multiple Possible Value-Creating Catalysts over Next 18 Months
MGL-3196: First-in-Class Thyroid Hormone Receptor (THR)-β Agonist
Large & Underserved Markets in NASH & Genetic Lipid Disorders
Seasoned Management Team
1
2
3
4
Madrigal’s Team: Led by an Experienced Management Team with Multiple Successful NDA/MAAs and Marketed Products
4
Paul Friedman, M.D.
Chairman and CEO
Former CEO of Incyte
Former President of R&D at Dupont Pharmaceuticals
Marc Schneebaum
CFO, SVP
Former CFO, SVP at Synta
Former CEO at Predictive Biosciences
Rebecca Taub, M.D.
CMO, EVP R&D
Founder of Madrigal
Aided in discover of Eliquisand MGL-3196 at Roche
Pipeline: Madrigal has Two Phase 2 Programs with Multiple Near-Term Catalysts
Compound Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Upcoming Catalysts
MGL-3196Thyroid Hormone Receptor-β (THR-β) Agonist
Nonalcoholic Steatohepatitis (NASH)
Phase 2 liver biopsy data
Phase 3 initiation
Familial Hypercholesterolemia
(FH)
Topline Phase 2 data
Phase 3 initiation
MGL-3745THR-β Agonist
NASH and FH
5
Madrigal is focused on the development of its pipeline of THR-β agonists for the treatment of NASH and Familial Hypercholesterolemia (FH)
Unmet Need: Madrigal Aims to Treat Patients with NASH, a Large and Underserved Population
6
~3-5% of the US population has NASH
NAFLD is the most common liver disease world-wide~25% of US population
Rapid progression, <2 years 25% of NASH Stage 3 fibrosis progress to cirrhosis
NASH is the most severe form of nonalcoholic fatty liver disease (NAFLD)
Characterized by inflammation and damage caused by a buildup of fat in the liver that leads to cirrhosis, fibrosis, and cell death
Develops most often in patients with obesity/metabolic syndrome, diabetes and dyslipidemia
NASH represents an indication with significant unmet need
Estimated to affect 3-5% of the US adult population
Expected to be the leading cause of liver transplant
There are currently no approved therapies for the treatment of NASH
American Liver Foundation, Aliment Pharmacology TherapyWGO (World Gastroenterology Organization) 2012
Mechanism of Action: The Importance of Liver THR-β in NASH
The THR-β receptor mediates the beneficial effects of thyroid hormone in the liver, on LDL-cholesterol and triglycerides, fatty liver and insulin sensitivity
THR-β agonists reduce liver fat through breakdown of fatty acids, and stimulate mitochondrial biogenesis in the NASH liver, thus, we believe, reducing lipotoxicity and improving liver function
We believe MGL-3196 has pleiotropic effects characteristic of an “ideal” NASH drug, with potential for addressing the underlying metabolic syndrome and hallmark features of NASH: steatosis/lipotoxicity, inflammation, ballooning, fibrosis (both directly and indirectly)
We believe treating NASH, rather than fibrosis, is key to addressing the disease
—Resolution of NASH, without reducing fibrosis, is an approvable endpoint —Recognition that liver fibrosis will decrease with time after NASH resolves (similar to reduction
of fibrosis as the liver regenerates after cure of HCV)
7
We believe that MGL-3196, a selective THR-β agonist, will treat the underlying disease in NASH patients
Clinical Gastroenterology,2003;37(4):340-343 J Clin Endocrinol Metab.2016; 101(8:3204-3211
Hepatology. 2015;61:1547-54, Gastroenterology, 2015;149:389-97 Cell Biosci (2016) 6:46
Safety: Addressing Safety is Critical; Highly Selective THR-βAgonist Avoids Off-target Effects
8
*** ******
***
p<.05*p<.01**P<.001***
******
*** *** *****
T3
MGL-3196
High selectivety for THR- β may reduce toxicity, which is mediated through the systemic THR-α receptor
Very high protein binding, low penetration of tissues outside the liver including brain, heart and bone also expected to limit toxicity
MGL-3196 treated healthy volunteers and patients show normal central thyroid axis and vital signs
Unlike thyroid hormone (T3), MGL-3196 decreases cholesterol without impact on bone or cartilage in preclinical studies
Adverse Events (AEs) mostly mild, similar to control without safety or tolerability issues in Phase 1 and twelve week interim NASH Phase 2 readout
24d study in 40 week old diet-induced obese (DIO) mice on High Fat Diet (HFD) for 38 weeksIllustrative comparison of MGL-3196 to other molecules
Selective Mechanism of Action Strong Preclinical and Clinical Safety Data
J Med Chem. 2014;57(10):3912-3923 BMJ 2011;342:d2238
Preclinical: MGL-3196 Proof-of-Concept Well Established in Animal Models
9
Reduced Hepatic TGs Improved Insulin Sensitivity
Reduced Liver Enzymes Improved Liver Histology All NASH Components
Liver Triglycerides
***
** *
***
* p<0.05
*
Insulin Tolerance Test (0.5 U/kg insulin)
ALT
************
Liver Fat (Histology)
MGL-3196Control
Upper panels: 24d study in 17 wk old DIO mice (po, qd) on high fat diet (HFD) 13 wks; lower panels: 24d study in 40 wk old DIO mice on HFD 35 wks
Phase 1: Robust LDL and Triglyceride Lowering Established in 14 Day Multiple Ascending Dose Study
Once daily oral treatment led to highly statistically significant and dose-dependent up to ~30% reduction of apolipoprotein B (ApoB), total, LDL, non-HDL cholesterol; Strong trends in triglyceride reduction up to 60%; Near maximal effect at 80 mg dose
Change from Baseline (CFB) by mean % CFB calculated for each individual subject 24h after 14th dose; baseline value obtained just prior to first dose; ApoB, apolipoprotein B; Chol, total cholesterol; LDL-C, LDL cholesterol directly measured; Non-HDL-C, non-HDL cholesterol; TG, triglycerides (median %CFB)
*** p<0.001 ** p<0.01 * p≤0.05 “p≤0.1
******
******
*** ******
********
****
* *
*
*
“
“
10Atherosclerosis 230 (2013) 373-380
Six dose cohorts, 36 total healthy volunteers dosed daily with MGL-3196 (5, 20, 50, 80, 100, or 200 mg) and 12 with placebo for 14 days
Healthy volunteers with slightly elevated LDL cholesterol (> 110 mg/dL)
Well-tolerated, appeared safe at all doses tested
No effect on vital signs, heart rate, central thyroid axis, or liver enzymes
Phase 2: MGL-3196 Trial Design is Targeted at Highly Relevant Primary and Secondary Endpoints
11
Inclusion/Exclusion
NASH on liver biopsy: NAS≥4 with fibrosis
≥10% liver fat on MRI-PDFF
Include diabetics, statin therapy
Comparator/Arms
MGL-3196 or Placebo, once daily
Primary Endpoint
Reduction of liver fat (MRI-PDFF) at 12 weeks
Secondary Endpoints
NASH biomarkers and lipids at 12, 36 weeks
Repeat MRI-PDFF at 36 weeks
Liver biopsy at 36 weeks - reduction/resolution of NASH in patients on drug; reduction of fibrosis
Design
Stage
Drug MGL-3196
Blinded 2:1
Phase 2
Number of Patients
Centers
Treatment Duration
125, Fully Enrolled
~30, USA
36 Weeks
Study Overview Study Details
Phase 2: MGL-3196 Study Achieved Primary Endpoint in Interim Readout
12
ALL MGL-3196
HIGH MGL-3196¹
Placebo
Number of patients 78 44 38
Primary Endpoint:Relative change in MRI-PDFF (% change from baseline, median)Significance relative to placebo
-36.3%
p<0.0001
-42.0%
p<0.0001
-9.6%
Percentage of patients attaining ≥30% liver fat reductionSignificance relative to placebo
60.3%
p<0.0001
75.0%
p<0.0001
18.4%
Statistically significant improvements in low-density lipoprotein cholesterol (LDL-C), triglycerides and lipoprotein (a) Lp(a)²
Statistically significant improvements in liver enzymes in drug-treatment group²
Very good all subject tolerability: mostly mild and a few moderate AEs, the numbers of which are balanced between placebo and drug-treated groups; 3 reported SAEs all considered unrelated to drug
Two regularly scheduled DSMB meetings held May 2017 and September 2017 to review data from the Madrigal NASH Phase 2 trial. DSMB recommended to continue the trial with no changes to the protocol
¹ Prespecified group of patients (44/78) with relatively higher MGL-3196 drug levels² These beneficial effects are more pronounced in the group of pre-specified patients with
higher levels of MGL-3196Ther. Adv. Gastroenterol. 2016; 9:692-701
Excellent correlation between decline in fat content on MRI-PDFF and NAS score, steatosis and ballooning on biopsy
Competitive Position: MGL-3196 Well-Positioned in the NASH Landscape
Pleiotropic and cardio-beneficial actions position MGL-3196 as potential best-in-class NASH therapeutic
Opportunities for differentiation from other NASH agents
Efficacy on NASH and cardiovascular endpoints position MGL-3196 to be used in combination with anti-fibrotic and/or anti-inflammatory agents
13
Targetcompound
NAS Score
FibrosisScore Liver Lipids
NASH Prevention
Insulin Sensitivity LDL TGs
CV Risk Side Effects
FXR ✔ ✔ ✔ ✔ ✔ — LDL-C Pruritus
Anti-fibrotic ? ✔ — ✖ — — — ? Unknown
PPARαδ ✔ ✖ — ? ✔ PPARα/δ Well-tolerated
Anti-inflam ✔ ? — — — — — ? Well-tolerated
Pioglitazone ✔ ✔ ✔ ✔ ✔ PPAR CHF,bone,weight
MGL-3196 ✔ ✔ ✔ ✔ ✔ CV Benefit Well-tolerated
Lancet 385:956-65; 2015; Gastroenterology Feb 11 2016; pii:S0016-5085(10)00140-2Tobira press release July 25, 2016; Ann Intern Med. doi:10.7326/M15-1774 2016
FH: In addition to NASH, Madrigal also Targeting Familial Hypercholesterolemia in Phase 2 Trials
14
HeFH and HoFH caused primarily by inactivating mutations in LDL receptor
Early onset cardiovascular disease, HoFH < age 20
Associated with several of potentially severe cardiovascular diseases including coronary heart disease, carotid artery disease, and chronic kidney disease
Severe Debilitating
Dyslipidemia
Novel Therapeutic Approaches
Needed
1/200-1/500 HeFH; 1/250,000-1/1,000,000 HoFH
Higher frequency in certain genetically homogeneous populations
High prevalence for a genetic disease
High Genetic Prevalence
Despite current and newer therapies, HoFH and most HeFH not achieving treatment goals on standard care
Significant commercial opportunity for MGL-3196 in HoFH, refractory HeFH
European Heart Journal doi:10.1093/eurheartj/ehu274; 2014
FH: Phase 2 HeFH Clinical Trial with Anticipated Readout in 1Q 2018
15
Inclusion/Exclusion
HeFH on maximally tolerated statins (typically high dose), ezetimibe
Comparator/Arms
MGL-3196 or Placebo, once daily
Primary Endpoint
LDL cholesterol lowering
Secondary Endpoints
TGs, Lp(a), ApoB lowering
Safety
Design
Stage
Drug MGL-3196
2:1
Phase 2
Number of Patients
Centers
Treatment Duration
116, fully enrolled
13, Europe
12 weeks
Study Overview Study Details
Catalysts: Our Expectations for Development Timing
Completion of long-term toxicology studies for MGL-3196
Completion of Phase 1 trial of MGL-3196 dosed with statins for NASH
Initiation of Phase 2 trial of MGL-3196 for NASH
16
Initiation of 12-week Phase 2 trial of MGL-3196 for HeFH
Positive topline 12-week data from Phase 2 trial of MGL-3196 for NASH
Upcoming Catalysts:
36-week topline liver biopsy data from Phase 2 trial of MGL-3196 for NASH
Topline data from Phase 2 trial of MGL-3196 for HeFH
Phase 3 NASH
Phase 3 HeFH
Completed Milestones:
2018+20172016
17
Madrigal Investment Highlights
Multiple Possible Value-Creating Catalysts over Next 18 Months
MGL-3196: First-in-Class Thyroid Hormone Receptor (THR)-β Agonist
Large & Underserved Markets in NASH & Genetic Lipid Disorders
Seasoned Management Team
1
2
3
4
18
Appendix:
Additional Material
THR-β Agonism: Expected Direct Anti-Fibrotic Actions
• Fat deposition, lipotoxicity and resultant local inflammation are seen in NASH
• Hepatocyte dysregulation and damage ensue up to and including apoptosis. These perturbations lead to a profibrotic environment through:
• Ongoing inflammation;• Production by the dysregulated / damaged / dying hepatocytes of profibrotic factors,
with TGF-β among the most important
• Thyroid hormone receptor agonism has been shown to dampen inflammation in vivo and to inhibit TGF-β signaling in cell culture and in vivo
• In animal models of liver fibrosis, the extent of fibrosis is decreased by thyroid hormone administration and increased if thyroid hormone receptors are knocked out (PNAS 113: 3451, 2016)
• THR-β is the operative receptor in hepatocytes
19
THR-β: Decreased Liver Fibrosis and Apoptosis
20
• THR-β knockout and hypothyroid mice have delayed liver regeneration, increased apoptosis (PLoS ONE 5(1): e8710, 2010)
• THR-β -/- mice have increased liver fibrosis with age
• Treatment with thyroid hormone reduces fibrosis in animal models of liver fibrosis (PNAS 113: 3451, 2016)
MGL-3196, a First-in-Class Liver-Directed THR- β Agonist
• We believe MGL-3196 is the first bona fide THR-β selective molecule with key advantages over previous companies’ analogues• Discovery of MGL-3196 and backups at Roche utilized a novel functional assay that went beyond what previous companies
had done (simple receptor binding assay)• Earlier compounds from other companies, purported to be THR-β selective, show no functional selectivity in this
assay and, like thyroid hormone, activate the THR-α receptor equally well as the β receptor• in vivo data confirm MGL-3196’s high liver uptake and preclinical safety: no heart, bone/cartilage, or brain uptake; safe in
long-term animal toxicology studies• Avoids activity at the systemic THR-α receptor (increased heart rate, osteoporosis) • Unlike other company’s earlier thyroid receptor agonists, no cartilage findings in chronic toxicology or liver enzyme
increases in human studies
Thyroid Gland
Liver T4 T3
T4 T3
Nuc T
hyro
id H
orm
one
Rece
ptor
α o
r β
TSH
Thyroid Hormone Pathway
T4
T4, prohormoneT3, active hormoneTSH, thyroid stimulating hormone
less α potent
m
ore ß selective
α-potency (nM)
β/α relative to T3
-5
0
5
10
15
20
25
30
35
-500 500 1500 2500 3500 4500
Thyroid Hormone (T3) MB07811 (GC1)MGL-3196 EprotiromeKB
GC-1
21J Med Chem. 2014;57(10):3912-3923
MGL-3196 Agonism of Hepatic THR-β
• In livers of euthyroid individuals T3 induces about half the maximal transcriptional activity of THR-beta
• MGL-3196 can further beneficially increase this transcriptional activity as we have shown in euthyroid animal models and humans.
• Interestingly, systemic hypothyroidism, at the level of the thyroid gland itself, leads to increases in plasma lipids (LDL-C and triglycerides) and increases the risk of nonalcoholic fatty liver disease.
• In fact, actual NASH is at least twice as common in hypothyroid individuals as in the general population.
• Further, liver-specific hypothyroidism is present in human NASH, caused by degradation of thyroid hormone (increased deiodinase 3 produced by stellate and inflammatory cells) in the NASH liver.
• In a vicious cycle this liver-specific hypothyroidism increases as NASH progresses. • Thus, MGL-3196, which is not affected by deiodinases, can increase transcriptional activity
over an even broader range than in the non-NASH euthyroid state.• With MGL-3196-induced resolution of NASH, with the concomitant decrease in numbers and
level of activation of stellate cells, normalization of hepatic thyroid function should occur.
22
MGL-3196: Reduction of Key NASH, Fibrosis Pathway Genes at Human Comparable Drug Levels
TIMP1 tissue inhibitor metalloproteinaseCTGF connective tissue growth factorSMA smooth muscle actinSAA serum amyloid ACRP C-reactive protein
“HFD”, lane 1 mean HFD gene expression normalized to mean Lean; Lanes (2-7) mean gene expression normalized to mean of DIO; “Rosi” (rosiglitazone, 3 mg/kg, 24 wks) Red, higher expression; blue decreased expression
Inflammation HFD Lean 0.1 0.3 1 3 RosiMCP-1/CCL2MIP-2α/CXCL2MIP-2ß/CXLCL3A20/TNFaip3CRPAnnexin 2SAA1FibrosisCollagen 1Galectin-3TIMP1Collagen 4a2SMACollagen 4a1CTGFKeratin 18Collagen 3Galectin-1
25 week study in lean control mice and HFD mice treated with Vehicle, 0.1 to 3 mg/kg MGL-3196 or Rosiglitazone (3mg/kg)
Bad Good
1 2 3 4 5 6 7
MGL-3196 (mg/kg)
23
MGL-3196: Radiographic Tissue Distribution22
24
• MGL-3196 is highly protein bound (>99%) and is taken up into the liver by hepatic transporters• The primary route of elimination after an oral dose of [14C]MGL-3196 in rats and dogs was the
feces via biliary excretion• Uptake was low to undetectable heart, bone and brain, further supporting the safety of MGL-
3196
MGL-3196: Long-term Dosing in Humans is Enabled
• Single Ascending Dose (SAD) study
• Multiple Ascending Dose (MAD) study • Six dose cohorts, 36 total HV dosed daily with MGL-3196 (5, 20, 50, 80, 100, or 200 mg) and 12
with placebo for 14 days• Healthy volunteers with slightly elevated LDL cholesterol (> 110 mg/dL)
• Well-tolerated, appeared safe at all doses tested• No effect on vital signs, heart rate, central thyroid axis, or liver enzymes
• Phase 1 studies dosing MGL-3196 with statins
• Series of GLP toxicology and CMC studies support all indications• Manufacturing and product formulation• Chronic toxicology package• Phase 2-enabling
Completed:
25Atherosclerosis 230 (2013) 373-380
Lipid Lowering in Additional Phase 1 Studies
26
Baseline (BL); triglycerides (TG) (all) or >150 mg/dL at BL; Lp(a) shown only for subjects with measurable BL Lp(a)
p<.003p <.0001
• In Phase 1 studies, 38 healthy volunteers were dosed with one-two days of a statin and multiple daily doses (9-11) of MGL-3196 (100 or 200 mg)
• Robust lipid lowering was observed (up to 60% LDL-C), subjects reaching an average LDL-C of 70 mg/dL, ApoB of 59 mg/dL
• Consistent with MAD data, subjects with higher MGL-3196 exposures did not demonstrate more lipid lowering.
p=.001
MGL-3196 Phase 2 NASH Study: Likelihood of Success
• Excellent correlation between decline in fat content on MRI-PDFF and NAS score, steatosis and ballooning on biopsy (Ther. Adv. Gastroenterol. 2016; 9:692-701)
• Rapid liver fat changes detectable with MRI-PDFF after caloric restriction and weight loss: easily detectable and near maximal by 6 weeks (PLoS One.2016; 11(4):E0153595)
• Two regularly scheduled DSMB meetings held May 2017 and September 2017 to review data from the Madrigal NASH Phase 2 trial
• DSMB recommended to continue the trial with no changes to the protocol
• Positive 12-week primary (MRI-PDFF) and secondary endpoint data provides significant additional confidence
27
We believe that the impressive preclinical NASH animal and human lipid lowering effects, positive 12-week data, and the excellent safety profile point to a high probability of success
NASH Phase 2 Demographics
Baseline Demographics
n 125
Mean age 50.4
Gender - n (%)
Female 63 ( 50.4)
Male 62 ( 49.6)
Ethnicity - n (%)
Not Hispanic or Latino 66 ( 52.8)
Hispanic or Latino 59 ( 47.2)
28
NASH Baseline Characteristics
Baseline
BMI (kg/m²) 35.07 (mean)
Type 2 diabetes n (%) 44 ( 35.2)
Hypertension n (%) 37 ( 29.6)
Triglycerides 172.0 (mean)
MRI-PDFF 20.17% FF (mean)
NAS at Screening 4.9 (mean)
Fibrosis score - (%)
1A, B 56%
2/3 43%
29
NAS score of at least 4, range 4-8 and fibrosis 1-3
Current Challenges in Treatment of FH
HoFH• Most patients still not reaching LDL-C goal • Newer agents, Lomitapide (Juxtapid, MTPi) and
Mipomersen (Kynamro, anti-ApoB) may have safety issues
• Both carry FDA label warning*, hepatotoxicity• Increased ALT and hepatic fat
• Elevated Lp(a) remains an issue
HeFH• In HeFH, standard care (statins, ezetimibe) most HeFH
still not achieving goal• Even with PCSK9 inh 40% not at target
• Further treatment opportunities include relative statin intolerance in some and elevated Lp(a)
HoFHLipid Lowering Therapy
LDL decrease
Conventional
Statins Up to 28%
Ezetimibe <10%
LDL apheresis 20-40%
New Treatment Options
Lomitapide Up to 50%
Mipomersen 25%
PCSK9 inh 23%
30Drugs. 2015; 75(15): 1715–1724*Kynamro, Juxtapid FDA label, prescribing information
MGL-3196: Unique and Complementary Lipid Lowering Profile
• Thyroid pathway clinically validated and differentiated in FH
• Both LDL receptor-dependent and –independent cholesterol lowering:• Stimulates cholesterol breakdown and elimination• Lowers ApoB and Lp(a)• Decreases levels of PCSK9 (human data) and angiopoietin-like protein 3 ANGPTL3
(gene expression)• MGL-3196 lowers LDL in concert with statins in clinical & preclinical studies• Thyroid agonists lower cholesterol in LDL receptor knockout mice*• In Phase 3 trials in HeFH, an earlier THR agonist lowered LDL cholesterol and Lp(a)**• MGL-3196 acts through a mechanism that potentially lowers Lp(a), a severely
atherogenic particle that is elevated in FH
31
In FH, we believe MGL-3196 will deliver additional LDL-C and Lp(a) lowering on top of conventional treatment
* Endocrinology 2012 Nov;153(11):5143-9** Lancet Diabetes Endocrinol2014; 2: 455–63
Proposed Phase 2a HoFH Clinical Trial Protocol
Study Study Details
Drug MGL-3196 Inclusion/Exclusion• HoFH on standard care, may include PCSK9ab, statins,
ezetimibe
Comparator/Arms• Patient is his own control• MGL-3196 may be titrated
Primary Endpoint• LDL cholesterol lowering
Secondary Endpoint• TGs, Lp(a), ApoB lowering• Safety
Design Open label
Stage Ph2
# Patients 6-8
Centers 6
Treatment duration
12 weeks
32